beta-苯基丙酰-L-苯丙氨酸 | 21888-30-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: beta-苯基丙酰-L-苯丙氨酸
• 英文名称: β-phenylpropionyl-L-phenylalanine
• 英文别名: hydrocinnamoyl-L-phenylalanine；N-phenethyl-L-Phe-OH；N-(3-phenylpropanoyl)-L-Phe-OH；N-(3-phenyl-propionyl)-L-phenylalanine；2S-2-(3-phenylpropionoyl)amino-2-phenylmethyl-acetic acid；N-(3-Phenyl-propionyl)-L-phenylalanin；N-(3-phenylpropionoyl)-L-phenylalanine；N-(3-phenyl propanoyl)-phenylalanine；beta-Phenylpropionyl-L-phenylalanine；(2S)-3-phenyl-2-(3-phenylpropanoylamino)propanoic acid
• CAS: 21888-30-2
• 化学式: C₁₈H₁₉NO₃
• 分子量: 297.354
• InChiKey: PKOVGZQJPDDEJO-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  beta-苯基丙酰-L-苯丙氨酸 在 sodium hydroxide 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 hydrocinnamoyl-L-phenylalanyl-L-glutamine
  参考文献：
  名称：

  Inhibition of Peptidylglycine .alpha.-Amidating Monooxygenase by N-Substituted Homocysteine Analogs

  摘要：

  C-terminal amidation is a posttranslational modification found in many neuropeptides. Peptidylglycine cl-amidating monooxygenase (PAM) catalyzes the synthesis of the biologically essential C-terminal amide from a glycine-extended precursor peptide. Reported herein are the first potent inhibitors of PAM. Dipeptides containing a C-terminal homocysteine and an N-acylated hydrophobic amino acid were found to inhibit PAM with IC(50)s in the low nanomolar range. Inhibition potency was dependent on both the carboxylate and the thiolate functionalities of the homocysteine and on the hydrophobic groups of the second amino acid. The thiolate was postulated to produce high binding affinities through coordination with the active-site copper. The compound series also exhibited potent inhibition of PAM in rat dorsal root ganglion cells as demonstrated by a dose-dependent increase in the substance P-Gly/substance P ratio. These results indicate that the compounds have sufficient potency and intracellular bioavailability to aid future studies focused on neuropeptide function and the contributions of neuropeptides to various disease processes.

  DOI：

  10.1021/jm00052a002
• 作为产物：
  描述：

  3-phenyl-2-(R)-(3-phenyl-propionylamino)-propionic acid 以 乙醇 为溶剂， 反应 12.0h， 以70%的产率得到beta-苯基丙酰-L-苯丙氨酸
  参考文献：
  名称：

  [EN] PROCESS FOR THE SEPARATION OF RACEMIC MIXTURES
  [FR] PROCEDE DE SEPARATION DE MELANGES RACEMIQUES

  摘要：

  本发明涉及一种用于分离混合物的方法，包括通过溶胶-凝胶工艺在硅胶上开发出具有所需对映体的更密集的分子印迹，该方法包括在所需对映体的存在下，通过水解控制聚合硅源作为单体和氨基烷基硅烷作为功能单体，对表面羟基进行封闭，并从硅胶中脱附封装的对映体。

  公开号：

  WO2004050586A1

文献信息

• Convenient Peptide Synthesis without Protection of <i>C</i>-Terminals
  作者：Takuya Noguchi、Naoka Tehara、Yuki Uesugi、Seunghee Jung、Nobuyuki Imai

  DOI：10.1246/cl.2012.42

  日期：2012.1.5

  Condensation of carboxylic acids 1 and 5 with unprotected α-amino acids 2 via activation by ethyl chloroformate and triethylamine proceeded effectively to afford the corresponding amides in 50–99% yields. Tripeptide 7c was obtained in 42% yield from the dipeptide 6c in a similar manner.

  羧酸1和5与未保护的α-氨基酸2在乙基氯甲酸酯和三乙胺的活化下高效缩合，以50-99%的产率得到相应的酰胺。类似地，从二肽6c中以42%的产率获得了三肽7c。
• Convenient primary amidation of N-protected phenylglycine and dipeptides without racemization or epimerization
  作者：Takuya Noguchi、Seunghee Jung、Nobuyuki Imai

  DOI：10.1016/j.tetlet.2013.11.042

  日期：2014.1

  Primary amidation of N-protected phenylglycine and dipeptide proceeded easily to afford the corresponding amides in 57–95% yields with 99% ee and 81–99% de, respectively. The procedure is very easy to avoid racemization and epimerization of the products in the reactions by keeping exactly the reaction temperature at −15 °C when the activation of carboxylic acids, followed by the reaction of the mixed

  N-保护的苯基甘氨酸和二肽的初次酰胺化反应容易进行，以57-95％的收率分别提供了99％ee和81-99％de的相应酰胺。通过在羧酸活化时将反应温度精确地保持在-15°C，然后使混合的碳羧酸酐与NH 4 Cl反应，该过程很容易避免反应中产物的外消旋和差向异构化。
• Phosphonic acid derivative having inhibitory activity against carboxypeptidase B
  申请人：Meiji Seika Kaisha Ltd.

  公开号：US20030119787A1

  公开（公告）日：2003-06-26

  A compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof: 1 wherein R 1 represents hydrogen atom, an alkyl group, a substituted alkyl group and the like; R 2 and R 3 represent hydrogen atom, an alkyl group, a substituted alkyl group, an alkoxyl group and the like; X represents —CH 2 —, —O—, or —NH—; A represents the following group (II): 2 [in which R 7 and R 8 represent hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group and the like; R 9 and R 10 represents hydrogen atom, a halogen atom, hydroxyl group, phenyl group, an alkyl group and the like] and the like; and E represents hydrogen atom and the like, which has inhibitory activity against carboxypeptidase B and is useful for therapeutic and/or preventive treatment of a thrombotic disease.

  以下是通用式（I）及其药学上可接受的盐所代表的化合物：其中R1代表氢原子、烷基、取代烷基等；R2和R3代表氢原子、烷基、取代烷基、烷氧基等；X代表—CH2—、—O—或—NH—；A代表以下基团（II）：其中R7和R8代表氢原子、烷基、酰基、烷氧羰基等；R9和R10代表氢原子、卤素原子、羟基、苯基、烷基等；E代表氢原子等，具有对羧肽酶B的抑制活性，可用于治疗和/或预防血栓性疾病。
• Phosphonic acid derivatives having carboxypeptidase b inhibitory activity
  申请人：Meiji Seika Kaisha Ltd.

  公开号：US06576627B1

  公开（公告）日：2003-06-10

  A compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof: wherein R1 represents hydrogen atom, an alkyl group, a substituted alkyl group and the like; R2 and R3 represent hydrogen atom, an alkyl group, a substituted alkyl group, an alkoxyl group and the like; X represents —CH2—, —O—, or —NH—; A represents the following group (II): [in which R7 and R8 represent hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group and the like; R9 and R10 represents hydrogen atom, a halogen atom, hydroxyl group, phenyl group, an alkyl group and the like] and the like; and E represents hydrogen atom and the like, which has inhibitory activity against carboxypeptidase B and is useful for therapeutic and/or preventive treatment of a thrombotic disease.

  以下是通式（I）及其药学上可接受的盐所代表的化合物： 其中，R1代表氢原子，烷基，取代烷基等；R2和R3代表氢原子，烷基，取代烷基，烷氧基等；X代表—CH2—、—O—或—NH—；A代表以下基团（II）： 【其中，R7和R8代表氢原子，烷基，酰基，烷氧羰基等；R9和R10代表氢原子，卤素原子，羟基，苯基，烷基等等；E代表氢原子等，具有对羧肽酶B的抑制活性，可用于治疗和/或预防血栓性疾病。】
• PHOSPHONIC ACID DERIVATIVES HAVING CARBOXYPEPTIDASE B INHIBITORY ACTIVITY
  申请人：Meiji Seika Kaisha, Ltd.

  公开号：EP1152004A1

  公开（公告）日：2001-11-07

  A compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof: wherein R1 represents hydrogen atom, an alkyl group, a substituted alkyl group and the like; R2 and R3 represent hydrogen atom, an alkyl group, a substituted alkyl group, an alkoxyl group and the like; X represents -CH2-, -O-, or -NH-; A represents the following group (II): [in which R7 and R8 represent hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group and the like; R9 and R10 represents hydrogen atom, a halogen atom, hydroxyl group, phenyl group, an alkyl group and the like] and the like; and E represents hydrogen atom and the like, which has inhibitory activity against carboxypeptidase B and is useful for therapeutic and/or preventive treatment of a thrombotic disease.

  由以下通式（I）代表的化合物及其药理学上可接受的盐： 其中 R1 代表氢原子、烷基、取代的烷基等；R2 和 R3 代表氢原子、烷基、取代的烷基、烷氧基等；X 代表 -CH2-、-O- 或 -NH-；A 代表以下基团 (II)： [其中 R7 和 R8 代表氢原子、烷基、酰基、烷氧基羰基等；R9 和 R10 代表氢原子、卤素原子、羟基、苯基、烷基等]等；E 代表氢原子等，对羧肽酶 B 具有抑制活性，可用于血栓性疾病的治疗和/或预防。